Tesaro Announces Priority Review Designation for Niraparib NDA

WALTHAM, Mass., Dec. 20, 2016 (GLOBE NEWSWIRE) -- Tesaro, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review for the niraparib New Drug...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news